BarclaysTreats Novartis (NVS) With Care

Barclays Capital (NYSE: BCS) is not entirely convinced by Novartis’ (NYSE: NVS) ASH data on its new drug Tasigna’s superiority over the traditional Leukemia drug Gleevec.

Moreover, Novartis has not demonstrated its ability to protect profits into patent expiries. The resulting earning-risk has prompted Barclays to set the target price below current trading levels.